Isabel ALAK

Oncologa, llena de preguntas. Y ademas de la medicina muchas otras inquietudes #breastcancer #cancerdemama #oncologia #mendia #GEICAM #BIOGIPUZKOA

[Isabel ALAK @ALACIsabel]

@Larvol @DrRishabhOnco @ASCO Is that rankin important?

[Isabel ALAK @ALACIsabel]

@PTarantinoMD Agree

[Isabel ALAK @ALACIsabel]

@ANESTESIOLOCO No creo que cosas con tantos datos de un paciente se deban contar en una red social.

[Isabel ALAK @ALACIsabel]

@Dr_RShatsky @BianchiniGP No, 120 mg the dose for bone mets (Xgeva)

[Harold J. Burstein, MD, PhD, FASCO @DrHBurstein]

They saved some of the best for last @ASCO. Talks today on advanced breast cancer were excellent. Particularly important were the discussions by Meredith Regan @DanaFarber and Matt Goetz @MayoClinic. Both explored how to THINK about trials and data, and how to best use drugs.

[Baricorcho @Baricorcho]

@Dr_RShatsky IZABRIGHT-Breast01 Trial is ongoing, recruiting in Europe. First line TNBC Patients ineligible for immunotherapy.
Impressive drug profile in my short experience.

[Isabel ALAK @ALACIsabel]

@PTarantinoMD @drsarahsam Oral SERDs are as good as AI in general population and better than AI in ESR1 mutated. So they are quite eficacious.

[Harold J. Burstein, MD, PhD, FASCO @DrHBurstein]

Perhaps the most important breast cancer discussion this year at ASCO. A brilliant analysis of PFS2 and its meaning (or lack thereof) in advanced breast cancer. Required viewing for all clinical investigators.

[GEICAM - Cáncer de mama @GEICAM]

These days at #ASCO26, data from the Phase III FLAMINGO-01 trial, in which @GEICAM is participating alongside @GreenwichLS, were presented.

🆕 Preliminary injection site reaction data comparing vaccination over time in GLSI-100 treated non-HLA-A*02 patients showed a significant increase in immune response. Future studies may explore the use of immune responses to assess: correlation of DTH to ISRs, immunogenicity of GLSI-100 by specific HLA type, timing of boosters to sustain immunity, clinical site performance, and the discontinuation of treatment for non-responders.

🔝 GEICAM is represented on the Steering Committee of this study by Dr. Miguel Martín, and our Clinical Operations Executive Director, Gema Sanz, joined the Greenwich LifeSciences, team for the poster presentation.

#ASCO26 📍
@ASCO @ASCOPost @oncofir

We are pleased to share the poster, along with full information on these data, for all those who may be interested: ⤵️
https://t.co/9L1U6GnZz6

[Isabel ALAK @ALACIsabel]

@PTarantinoMD 😓😓

[Yakup Ergün @dr_yakupergun]

#ASCO26 abst 1064

CAPTURE showed that in post-CDK4/6 PIK3CA-mutant HR+/HER2− MBC, alpelisib + fulvestrant did not beat capecitabine.

PFS: 7.4 vs 9.4 months; ORR: 24% vs 50%.

In patients with visceral disease, the picture was even more in favor of capecitabine.

The presence of a biomarker alone does not define the right treatment sequence.

Beating capecitabine is not that easy!!!

I wonder how capivasertib + fulvestrant would have performed here?

[Isabel ALAK @ALACIsabel]

@joe_fenrir @DrSamuelBHume Because it is imposible…

[Isabel ALAK @ALACIsabel]

@PTarantinoMD Yes. But the trial do not answer tha question. The trial is not design to say when stop and continue with some kind of maintenance therapy. We need trials to answer that.

[Isabel ALAK @ALACIsabel]

@PTarantinoMD @DFCI_BreastOnc Large delta and even larger confidence interval

[Isabel ALAK @ALACIsabel]

@Dr_RShatsky Ufff, good and difficult question

[Isabel ALAK @ALACIsabel]

@farman4x 90

[Isabel ALAK @ALACIsabel]

@drsarahsam I hope a good prospective trial to be done. Retrospective data are too biased.

[Luca Arecco, MD @Lucarecco]

Alongside #ASCO26, the new ESMO metastatic breast cancer guidelines have just been published in @Annals_Oncology

Congrats to all co-authors, and a special mention to @myESMO mentor @E_de_Azambuja for this well-deserved recognition! 👏🏼
@OncoAlert

Link: https://t.co/AlUMSY6iTZ

[Isabel ALAK @ALACIsabel]

@NuoAntonio @Avivir Totalmente de acuerdo.